Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 21;387(3):277-280.
doi: 10.1056/NEJMc2206900. Epub 2022 Jul 6.

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines

Xin Zhao  1 , Rong Zhang  2 , Shitong Qiao  1 , Xiao Wang  3 , Weibing Zhang  4 , Wenjing Ruan  1 , Lianpan Dai  1 , Pengcheng Han  5 , George F Gao  6
Affiliations

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines

Xin Zhao et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralizing Antibodies against Omicron Subvariants Induced by ZF2001 and Inactivated Virus Vaccines.
Panel A shows the mutations in the spike protein of omicron subvariants BA.1, BA.1.1, BA.2, BA.2.12.1, BA.3, BA.4, and BA.5. (The latter two subvariants are grouped together because they have the same spike protein.) The amino acid differences in omicron subvariant sequences from those in the SARS-CoV-2 prototype isolate (PT) — including substitutions, deletions, and insertions — are highlighted in gold. The third type of amino acid on the same locus is marked in red. Deletion mutations are shown as blank squares with background color. CT denotes C-terminal cytoplasmic domain, NTD N-terminal domain, RBD receptor-binding domain, SP signal peptide, S2 S2-protein subunit, and TM transmembrane domain. Panels B through G show the 50% pseudovirus neutralization titers (pVNT50) against the listed PT isolate and omicron subvariants BA.2, BA.2.12.1, BA.4, and BA.5. Samples are grouped according to the vaccine type and immunization strategy. The groups include 20 vaccinees who received three shots of the ZF2001 vaccine at 1-month intervals (Panel B); 9 vaccinees who had a 2-month interval between the second and third doses (Panel C); 15 vaccinees who had a prolonged interval (4 to 6 months) between the second and third doses (Panel D); 16 vaccinees who received three doses of an inactivated vaccine (Panel E); and 19 vaccinees who received two doses of an inactivated vaccine boosted by the ZF2001 vaccine (heterologous boost) (Panel F). In these five groups, samples were obtained approximately 1 month after the last dose had been administered. In the sixth group, samples from 16 vaccinees who had received three doses of the ZF2001 vaccine with a prolonged-interval strategy were obtained 4 to 7 months after the last dose (Panel G). The pVNT50 in each group is shown as the geometric mean titer (GMT) at the top of each panel, along with the factor reduction as compared with the PT isolate; the 𝙸 bars indicate 95% confidence intervals. The dashed horizontal line indicates the lower limit of detection for the pseudovirus neutralization assay. Values of less than 10 for the pVNT50 indicate a negative sample and were counted as 5. Similar data for subvariants BA.1, BA.1.1, and BA.3 are provided in Figure S2 in the Supplementary Appendix.
See this image and copyright information in PMC

References

    1. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 40. April 8, 2022. (https://assets.publishing.service.gov.uk/government/uploads/system/uploa...).
    1. Tegally H, Moir M, Everatt J, et al. Continued emergence and evolution of omicron in South Africa: new BA.4 and BA.5 lineages. May 2, 2022. (https://www.medrxiv.org/content/10.1101/2022.05.01.22274406v1). preprint.
    1. Han P, Li L, Liu S, et al. Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell 2022;185(4):630.e10-640.e10. - PMC - PubMed
    1. Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 omicron BA.2 spike. Cell 2022;185(12):2103.e19-2115.e19. - PMC - PubMed
    1. Xu K, Gao P, Liu S, et al. Protective prototype-beta and delta-omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 2022. April 27 (Epub ahead of print). - PMC - PubMed

MeSH terms

Supplementary concepts